| scholarly article | Q13442814 |
| P50 | author | Munir Pirmohamed | Q20127995 |
| David Lalloo | Q39911246 | ||
| Robert Heyderman | Q60016666 | ||
| Daniel Carr | Q62745919 | ||
| Joep J van Oosterhout | Q90233719 | ||
| P2093 | author name string | Andrea L Jorgensen | |
| Saye H Khoo | |||
| Ana Alfirevic | |||
| Mas Chaponda | |||
| Elena Cornejo Castro | |||
| P2860 | cites work | Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults | Q24246038 |
| HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol | Q24555784 | ||
| Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire | Q27679355 | ||
| HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage | Q28138607 | ||
| Medical genetics: a marker for Stevens-Johnson syndrome | Q28254047 | ||
| PyPop: a software framework for population genomics: analyzing large-scale multi-locus genotype data | Q30772038 | ||
| Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries | Q33574656 | ||
| Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis | Q34093134 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans | Q34172669 | ||
| Drug-specific T cells in an HIV-positive patient with nevirapine-induced hepatitis | Q34535603 | ||
| HLA-B*5701 screening for hypersensitivity to abacavir | Q34747145 | ||
| Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study | Q34749686 | ||
| HLA involvement in nevirapine-induced dermatological reaction in antiretroviral-treated HIV-1 patients | Q35079813 | ||
| Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent | Q36070182 | ||
| Idiosyncratic drug reactions: current understanding | Q36551883 | ||
| Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding | Q36639652 | ||
| Pharmacological interaction of drugs with immune receptors: the p-i concept. | Q36639657 | ||
| HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients | Q37414313 | ||
| Toxic epidermal necrolysis (Lyell syndrome). | Q38021481 | ||
| HLA and pharmacogenetics of drug hypersensitivity. | Q38037649 | ||
| The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients | Q38138617 | ||
| Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda | Q38878356 | ||
| Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts | Q40518038 | ||
| HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. | Q43978358 | ||
| Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals | Q44131292 | ||
| Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany | Q44319947 | ||
| Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study | Q44849439 | ||
| HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients | Q46185533 | ||
| Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients | Q46466409 | ||
| HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz | Q46732848 | ||
| HLA-DQ association and allele competition in Chinese narcolepsy | Q46990379 | ||
| Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study | Q47573593 | ||
| Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. | Q51892602 | ||
| Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients | Q57259673 | ||
| Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation | Q58483705 | ||
| Clinical detection and assessment of drug induced neurotoxicity | Q59488375 | ||
| Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver | Q60787038 | ||
| HLA-Cw8 primarily associated with hypersensitivity to nevirapine | Q79467338 | ||
| Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration | Q80124577 | ||
| HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients | Q84916386 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nevirapine | Q263713 |
| P304 | page(s) | 1330-1339 | |
| P577 | publication date | 2013-01-29 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population | |
| P478 | volume | 56 |
| Q39555733 | A pharmacogenetics study in Mozambican patients treated with nevirapine: full resequencing of TRAF3IP2 gene shows a novel association with SJS/TEN susceptibility |
| Q38836848 | A web resource for mining HLA associations with adverse drug reactions: HLA-ADR |
| Q38663764 | Advances in the Pharmacogenomics of Adverse Drug Reactions. |
| Q52719665 | An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity. |
| Q37389754 | Antimicrobial stewardship's new weapon? A review of antibiotic allergy and pathways to 'de-labeling'. |
| Q34075812 | Antiviral drug allergy. |
| Q38860427 | Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir. |
| Q91659814 | Associations between human leukocyte antigen polymorphisms and hypersensitivity to antiretroviral therapy in patients with human immunodeficiency virus: a meta-analysis |
| Q34495636 | CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations |
| Q90404370 | Conference report: pharmacogenomics in special populations at WCP2018 |
| Q58774245 | Critical assessment of approaches for molecular docking to elucidate associations of HLA alleles with adverse drug reactions |
| Q52346835 | Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention. |
| Q26800980 | Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response. |
| Q27692095 | Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy. |
| Q43453078 | Frequencies of immune hypersensitivity reaction-associated HLA class I alleles in healthy South African Indian and mixed ancestry populations determined by a novel real-time PCR assay. |
| Q61639626 | Genetic Basis of Delayed Hypersensitivity Reactions to Drugs in Jewish and Arab Populations |
| Q24202114 | Genetic testing for prevention of severe drug-induced skin rash |
| Q35776000 | Genome-Wide Scan and Test of Candidate Genes in the Snail Biomphalaria glabrata Reveal New Locus Influencing Resistance to Schistosoma mansoni |
| Q33589777 | Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population |
| Q33582530 | Genotyping for severe drug hypersensitivity |
| Q54466096 | HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis susceptibility in a population from Mozambique. |
| Q47320133 | HLAs: Key regulators of T-cell-mediated drug hypersensitivity. |
| Q26782686 | Human Leukocyte Antigen Diversity: A Southern African Perspective |
| Q30238992 | Human leucocyte antigen-adverse drug reaction associations: from a perspective of ethnicity. |
| Q40130609 | Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility |
| Q50848412 | Institutional profile: the Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK. |
| Q55667533 | Interaction of Nevirapine with the Peptide Binding Groove of HLA-DRB1*01:01 and Its Effect on the Conformation of HLA-Peptide Complex. |
| Q97549977 | Mechanistic insights into antiretroviral drug-induced liver injury |
| Q64269386 | Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity |
| Q26853274 | Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities |
| Q58799157 | Pharmacogenetic Markers of Drug Hypersensitivity in a Thai Population |
| Q47357309 | Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments |
| Q34977413 | Pharmacogenomics of antimicrobial agents |
| Q30400366 | Pharmacogenomics of off-target adverse drug reactions |
| Q37544678 | Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi |
| Q64285801 | Prevention and Diagnosis of Severe T-Cell-Mediated Adverse Drug Reactions: Are We There Yet? |
| Q50115047 | SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. |
| Q41927200 | Severe Delayed Drug Reactions: Role of Genetics and Viral Infections. |
| Q55060097 | Severe cutaneous adverse reactions to drugs. |
| Q40089040 | Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles |
| Q38611191 | Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update |
| Q38629821 | Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction |
| Q34971993 | T cell-mediated hypersensitivity reactions to drugs |
| Q37626751 | The HLA-A*31:01 allele: influence on carbamazepine treatment |
| Q28080256 | The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity |
| Q52640903 | The Medication Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison to the USA FDA Label. |
| Q42700015 | Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes |
Search more.